3-(4-甲基-1-哌嗪)-3-氧丙腈 | 15029-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-(4-甲基-1-哌嗪)-3-氧丙腈
• 英文名称: 3-(4-methylpiperazin-1-yl)-3-oxopropanenitrile
• 英文别名: 1-Cyanacetyl-4-methyl-piperazin
• CAS: 15029-34-2
• 化学式: C₈H₁₃N₃O
• mdl: MFCD02186990
• 分子量: 167.211
• InChiKey: DJWSZBRFBMIGIW-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  330.5±37.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  47.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  3-(4-甲基-1-哌嗪)-3-氧丙腈 在 lithium aluminium tetrahydride 、 sodium hydroxide 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 14.0h， 生成 1-aminomethyl-1-(4-methylpiperazinomethyl)cyclopentane
  参考文献：
  名称：

  Synthesis of perhydro-N-(2,2-disubstituted-3-aminopropyl) heterocycles as potentially bioactive compounds and fragments for combinatorial chemistry

  摘要：

  摘要：描述了一种新的制备perhydro-­N-(2,2-二取代-3-氨基丙基)杂环化合物的方法，该方法可通过简单的程序获得大量相应衍生物，产率高至中等。

  DOI：

  10.1515/hc-2012-0093
• 作为产物：
  描述：

  N-甲基哌嗪 、 氰乙酸甲酯 以80%的产率得到3-(4-甲基-1-哌嗪)-3-氧丙腈
  参考文献：
  名称：

  Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases

  摘要：

  The 3-aryl-2-cyanoacrylamide scaffold was designed as core pharmacophore for inhibitors of the Dengue and West Nile virus serine proteases (NS2B-NS3). A total of 86 analogs was prepared to study the structure-activity relationships in detail. Thereby, it turned out that the electron density of the aryl moiety and the central double bond have a crucial influence on the activity of the compounds, whereas the influence of substituents of the amide residue is less relevant. The para-hydroxy substituted analog was found to be the most potent inhibitor in this series with a K(i)-value of 35.7 mu M at the Dengue and 44.6 mu M at the West Nile virus protease. The aprotinin competition assay demonstrates a direct interaction of the inhibitor molecule with active centre of the Dengue virus protease. The target selectivity was studied in a counterscreen with thrombin and found to be 2.8:1 in favor of DEN protease and 2.3:1 in favor of WNV protease, respectively. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.061

文献信息

• KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：Imago Biosciences, Inc.

  公开号：US20160237043A1

  公开（公告）日：2016-08-18

  Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

  本文披露了新化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制KDM1A的方法，增加γ球蛋白基因表达的方法，以及诱导人类或动物主体中癌细胞分化的方法，用于治疗急性髓性白血病等疾病。
• [EN] THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS<br/>[FR] COMPOSÉS DE THIAZOLOPYRIDINE, COMPOSITIONS ET LEUR UTILISATION COMME INHIBITEURS DE LA KINASE TYK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015091584A1

  公开（公告）日：2015-06-25

  Provided are thiazolopyridine compounds that are inhibitors of TYK2 kinase, compositions containing these compounds and methods for treating diseases mediated by TYK2 kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where X, R0, R1, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by TYK2 kinase in a patient.

  提供了一些噻唑吡啶化合物，这些化合物是TYK2激酶的抑制剂，包含这些化合物的组合物以及治疗由TYK2激酶介导的疾病的方法。具体来说，提供了符合Formula (I)、(II)或(III)的化合物，其立体异构体、互变异构体、溶剂合物、前药或其药用可接受的盐，其中X、R0、R1、R2、R3、R4和R5在此有定义，包括该化合物和药用可接受的载体、辅料或溶剂的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有TYK2激酶介导的疾病或症状的患者。
• KINASE INHIBITORS
  申请人：Taunton, JR. John William

  公开号：US20130035325A1

  公开（公告）日：2013-02-07

  Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.

  使用具有烯烃基团的激酶抑制剂抑制激酶的方法被披露。
• Synthesis of novel chromene scaffolds for adenosine receptors
  作者：Marta Costa、Filipe Areias、Marian Castro、Jose Brea、María I. Loza、Fernanda Proença

  DOI：10.1039/c1ob05305a

  日期：——

  A one-pot procedure was developed for the synthesis of novel 3-[amino(methoxy)methylene]-2-oxo-3,4-dihydro-2H-chromen-4-yl)-3-cyanoacetamides and chromeno[3,4-c]pyridine-1-carbonitriles from the reaction of 2-oxo-2H-chromene-3-carbonitriles and cyanoacetamides. These chromene derivatives were identified as new scaffolds for adenosine receptors and the hits 3a, 3c, 5a, and 5b were found.

  开发了一种一锅法，用于合成新型3- [氨基（甲氧基）亚甲基] -2-氧代-3,4-二氢-2 H-铬基-4-基）-3-氰基乙酰胺和铬基[3， 2-氧-2- H-苯甲基-3-腈与氰基乙酰胺的反应生成4- c ]吡啶-1-腈。这些色烯衍生物被确定为新的支架腺苷发现受体和命中3a，3c，5a和5b。
• HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20160311817A1

  公开（公告）日：2016-10-27

  Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式I的化合物或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11如本文所定义。还公开了制备这些化合物的方法以及将这些化合物用于治疗炎症性疾病如关节炎的方法。